5. Conclusions
Our study demonstrates the first proteomics characteristic of SMPP and
GMPP and provides FCGBP as new serum biomarker indicating the progress
of SMPP. In addition, sirolimus, a MTOR inhibitor, is a promising drug
target for the treatment of SMPP.
Acknowledgments. We would like to thank all patients who donate
their serum sample selflessly.
Disclaimer. The funders had no roles in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
Funding. This study was supported by
CAMS Innovation Fund for Medical
Sciences (CIFMS) (Grant No.
2019-I2M-1-003), Natural Science
Foundation of China (81741060) and Beijing Municipal Natural Science
Foundation (7182051).
Conflict of interest statement. All authors declare that there
is no conflict of interest.